Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.02.2016 | original report | Ausgabe 1/2016

memo - Magazine of European Medical Oncology 1/2016

TruSight Cancer Sequencing Panel reveals pharmacogenetic variants associated with sensitivity to chemotherapy in lung cancer

Zeitschrift:
memo - Magazine of European Medical Oncology > Ausgabe 1/2016
Autoren:
N. Chilingirova, Z. Hammoudeh, L. Balabanski, S. Ivanov, R. Vazharova, D. Nikolova, Prof. G. Kurteva, D. Toncheva, P. Chilingirov
Wichtige Hinweise
N. Chilingirova, Z. Hammoudeh, G. Kurteva, D. Toncheva, P. Chilingirov equally contributed to this work.

Abstract

Lung cancer is the most common cause of cancer death worldwide, and its prognosis and treatment response rate as well as the survival rate remain poor. In our study, we performed next generation sequencing (NGS) with cancer panel (Illumina) for 19 Bulgarian patients with both non-small cell lung cancer (NSCLC; 18 patients) and neuroendocrine tumor (1 patient) and focused on common polymorphisms which define proven or reported sensitivity to platinum-based therapy. We report reference SNP (rs)1042522 (TP53), rs2228001 (XPC), rs2227983 (EGFR), rs1799793, and rs13181 (ERCC2) single nucleotide polymorphism variants which have been detected in our patients in homozygous and/or heterozygous state. Therefore, we give important information to confirm the role of those polymorphisms in tumor resistance and recurrence after chemotherapy treatment. The results reveal that TruSight Cancer Panel could be a useful clinical tool for determining pharmacogenetic variants associated with the effect of chemotherapy.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2016

memo - Magazine of European Medical Oncology 1/2016 Zur Ausgabe